$ISTA News
Last published 5y ago
- 5y agoAFFYBOLTETNBPBAXU+389bio Announces Appointment of Kathy LaPorte to its Board of DirectorsGlobeNewswireSAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, to
- 14y agoISTALaw Firm Brower Piven Announces Investigation in Connection With the Acquisition of ISTA Pharmaceuticals, Inc. by Bausch + LombBusiness WireSTEVENSON, Md.--(BUSINESS WIRE)--The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) (“ISTA”) and other violations of state law by the board of directors of ISTA relating to the proposed acquisition of the company by Bausch + Lomb. The firm’s investigat ...
- 14y agoISTAHolzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of ISTA Pharmaceuticals, Inc.Business WireATLANTA--(BUSINESS WIRE)--Holzer Holzer & Fistel, LLC is investigating whether the directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the “Company”) (NASDAQ: ISTA) complied with their fiduciary duties in approving the proposed acquisition of the Company by Bausch & Lomb. According to the Company’s announcement, if the deal closes ISTA shareholders will receive $9.10 per share of ISTA owned. The in ...
- 14y agoISTARyan & Maniskas, LLP Announces Investigation of ISTA Pharmaceuticals, Inc.Business WireWAYNE, Pa.--(BUSINESS WIRE)--Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/ista) is investigating potential claims against the board of directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the "Company") (NASDAQ: ISTA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell ISTA to Bausch & Lomb in a transaction valued at approximately $50 ...
- 14y agoISTABernstein Liebhard LLP Announces Investigation of Offer for ISTA Pharmaceuticals, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Bernstein Liebhard LLP is investigating whether the Board of Directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the “Company”) (Nasdaq: ISTA) is breaching its fiduciary duty to its shareholders in failing to embrace premium offers for the company by Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”).